Welcome to our dedicated page for Iteos Therapeutics news (Ticker: ITOS), a resource for investors and traders seeking the latest updates and insights on Iteos Therapeutics stock.
Iteos Therapeutics, Inc. (ITOS) is a clinical-stage biopharmaceutical leader advancing novel immuno-oncology therapies designed to counteract cancer's immunosuppressive mechanisms. This page provides investors and researchers with timely, verified updates on the company's clinical developments, strategic partnerships, and scientific milestones.
Discover comprehensive coverage of clinical trial progress, regulatory filings, and research innovations across Iteos' pipeline programs. Key focus areas include updates on their adenosine A2A receptor antagonist, TIGIT-targeted antibodies, and other therapies addressing tumor microenvironment challenges.
All content is curated to provide stakeholders with actionable insights while maintaining strict compliance with financial disclosure standards. Users can expect neutral reporting on material events without speculative analysis, ensuring reliable information for informed decision-making.
Bookmark this page for streamlined access to Iteos' latest announcements, including earnings reports, patent developments, and collaboration news. Regularly updated to reflect the company's progress in advancing next-generation cancer immunotherapies.
iTeos Therapeutics (NASDAQ: ITOS) reported its Q1 2021 financial results, highlighting a cash balance of $321.4 million to support ongoing clinical advancements. The company is progressing in its development of two lead programs, EOS-448 and inupadenant, with significant clinical data expected before the end of 2022. EOS-448 showed promising initial results in its Phase 1 trial, while inupadenant's updated data will be presented at the upcoming ASCO Annual Meeting. R&D expenses increased to $11.6 million, reflecting heightened clinical activity.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) will host a conference call and live webcast on May 13, 2021, at 4:30 p.m. ET to discuss its first quarter 2021 financial results and provide a corporate update. The company focuses on developing immuno-oncology therapeutics, with key programs including EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist. Both candidates are currently undergoing clinical trials to evaluate their effectiveness in treating advanced solid tumors.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) has appointed Dr. Tony Ho and Dr. Robert Iannone to its Board of Directors, enhancing the company's expertise in clinical drug development. CEO David Hallal emphasized their vast experience in driving oncology products through clinical phases, which will be crucial as iTeos progresses its EOS-448 and inupadenant programs. Both appointees have significant backgrounds in the pharmaceutical industry, which may accelerate iTeos' immuno-oncology pipeline aimed at improving cancer treatment outcomes.
iTeos Therapeutics (NASDAQ: ITOS) announced initial results from its Phase 1/2a trial for EOS-448, an anti-TIGIT antibody, showing it was well tolerated without dose-limiting toxicities. In a cohort of 22 patients, EOS-448 demonstrated a partial response in one pembrolizumab-resistant melanoma patient and stable disease in several others. The company plans to advance EOS-448 into combination trials with pembrolizumab and conduct further analysis on its effectiveness against various advanced cancers. A conference call is scheduled for April 12 to discuss the findings.
iTeos Therapeutics (ITOS) announced significant developments in their clinical programs, including initial Phase 1/2a trial data for EOS-448 to be presented at the AACR Annual Meeting on April 12. The company reported a strong cash position of $336.3 million, enabling ongoing clinical advancements and investment in research. Inupadenant (EOS-850) is also in a multi-arm trial, with updates expected later in 2021. The firm is making strides in immuno-oncology, aiming to nominate an additional product candidate by year-end.
iTeos Therapeutics announced CEO Michel Detheux will present at two upcoming virtual investor conferences. The Cowen 41st Annual Health Care Conference is scheduled for March 2, 2021, at 11:50 a.m. ET, while the H.C. Wainwright Global Life Sciences Conference will take place on March 9, 2021, at 7:00 a.m. ET. Live webcasts will be available on the company's website, with archived replays for about 30 days. iTeos focuses on developing immuno-oncology therapeutics, including inupadenant and EOS-448, to improve cancer treatment.
iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the virtual 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021. Michel Detheux, PhD, President and CEO, will lead a fireside chat at 3:00 p.m. ET. The live webcast will be accessible on the company’s website, with an archived replay available for 30 days. iTeos is focused on developing innovative immuno-oncology therapeutics, including inupadenant and EOS-448, targeting critical pathways in the tumor microenvironment.
iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Michel Detheux, will present a company overview at the 39th Annual J.P. Morgan Conference on January 12, 2021, at 9:10 a.m. ET. The presentation can be viewed live on their website, with an archived version available for 30 days. iTeos is focused on developing innovative immuno-oncology therapeutics, including two clinical-stage programs: EOS-850 and EOS-448, targeting specific immuno-oncology pathways to enhance cancer therapy.
iTeos Therapeutics (Nasdaq: ITOS) announced participation in the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The fireside chat will be available on-demand for registered attendees. iTeos specializes in developing advanced immuno-oncology therapeutics, focusing on two clinical-stage programs: EOS-850, an adenosine A2a receptor antagonist, and EOS-448, targeting TIGIT. Both candidates are currently undergoing Phase 1/2a clinical trials for advanced solid tumors. For more details, visit their investor website.
iTeos Therapeutics (NASDAQ: ITOS) reported its Q3 2020 financial results, highlighting strong progress in clinical development for its lead candidates, EOS-850 and EOS-448, both in Phase 1/2a trials. Despite challenges from COVID-19 affecting patient enrollment, data readouts for EOS-850 and EOS-448 are on track for 1H 2021. The company's cash position increased to $340 million, enabling ongoing operations. R&D expenses rose to $8.7 million, driven by clinical activities. iTeos aims to nominate a new drug candidate by the end of 2021, supporting its growth in immuno-oncology therapeutics.
FAQ
What is the current stock price of Iteos Therapeutics (ITOS)?
What is the market cap of Iteos Therapeutics (ITOS)?
